TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2025-02-26
葉坤輝Yeh, Kun-Huei
- 計畫主持人
- 執行臨床試驗年資 23 年 9 個月
發表文獻
29筆
1
Chen KH, Hsu CL, Su YL, Yuan CT, Lin LI, Tsai JH, Liang YH, Cheng AL, Yeh KH. Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer. Br J Cancer. 2023 Jan;128(1):102-111. doi: 10.1038/s41416-022-02010-2. Epub 2022 Nov 1. PMID: 36319846; PMCID: PMC9814268.
2
Liang YH, Liang JT, Lin BR, Huang J, Hung JS, Lai SL, Chen TC, Tsai JH, Cheng YM, Tsao TH, Hsu WL, Chen KH, Yeh KH. Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer. J Formos Med Assoc. 2022 Oct;121(10):2057-2064. doi: 10.1016/j.jfma.2022.02.019. Epub 2022 Mar 11. PMID: 35288017.
3
Kuo SH, Yeh KH, Lin CW, Liou JM, Wu MS, Chen LT, Cheng AL. Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers (Basel). 2022 Feb 16;14(4):1005. doi: 10.3390/cancers14041005. PMID: 35205754; PMCID: PMC8869919.
4
Chou YJ, Kober KM, Yeh KH, Cooper BA, Kuo CH, Lin BR, Kuo TC, Tseng YJ, Miaskowski C, Shun SC. A pilot study of metabolomic pathways associated with fatigue in patients with colorectal cancer receiving chemotherapy. Eur J Oncol Nurs. 2022 Feb;56:102096. doi: 10.1016/j.ejon.2022.102096. Epub 2022 Jan 29. PMID: 35121410.
5
Chang FC, Chen TW, Huang TT, Lin WC, Liu JS, Chiang WC, Chen YM, Hsu C, Yeh KH, Chu TS. Spectrum of cancer patients receiving renal biopsy. J Formos Med Assoc. 2022 Jan;121(1 Pt 1):152-161. doi: 10.1016/j.jfma.2021.02.009. Epub 2021 Feb 25. PMID: 33640191.
6
Kang YK, Morita S, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Chen LT, Boku N. Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. Gastric Cancer. 2022 Jan;25(1):207-217. doi: 10.1007/s10120-021-01230-4. Epub 2021 Sep 4. PMID: 34480657; PMCID: PMC8732926.
7
Liang YH, Chen KH, Tsai JH, Cheng YM, Lee CC, Kao CH, Chan KY, Chen YT, Hsu WL, Yeh KH. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells. J Biomed Sci. 2021 Nov 10;28(1):75. doi: 10.1186/s12929-021-00769-9. PMID: 34758826; PMCID: PMC8579664.
8
Kuo SH, Yang SH, Wei MF, Lee HW, Tien YW, Cheng AL, Yeh KH. Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling. Cancer Cell Int. 2021 Aug 19;21(1):436. doi: 10.1186/s12935-021-02143-z. PMID: 34412631; PMCID: PMC8375138.
9
Chen KH, Lin LI, Yuan CT, Tseng LH, Chao YL, Liang YH, Liang JT, Lin BR, Cheng AL, Yeh KH. Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort. Br J Cancer. 2021 Jul;125(1):48-54. doi: 10.1038/s41416-021-01300-5. Epub 2021 Apr 12. PMID: 33846524; PMCID: PMC8257672.
10
Yang SH, Lu LC, Kao HF, Chen BB, Kuo TC, Kuo SH, Tien YW, Bai LY, Cheng AL, Yeh KH. Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. Oncoimmunology. 2021 Sep 27;10(1):1973710. doi: 10.1080/2162402X.2021.1973710. PMID: 34595057; PMCID: PMC8477954.
